Last reviewed 2026-06-10 · How we verify

SCID due to absent adenosine deaminase — Treatment Landscape & Competitive Intelligence

SCID due to absent adenosine deaminase (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating SCID due to absent adenosine deaminase, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Leadiant Biosci Inc · 1 drug in SCID due to absent adenosine deaminase

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in SCID due to absent adenosine deaminase:

• SCID due to absent adenosine deaminase treatment updates — RSS
• SCID due to absent adenosine deaminase treatment updates — Atom
• SCID due to absent adenosine deaminase treatment updates — JSON

Cite this brief

Drug Landscape (2026). SCID due to absent adenosine deaminase — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/scid-due-to-absent-adenosine-deaminase. Accessed 2026-06-10.

Related

• SCID due to absent adenosine deaminase full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing